Shots: The BTD is based on P-II 1346.9 clinical trial, which demonstrated that BI 425809 improved cognition in adult patients with schizophrenia Moreover, the company has initiated the P-III CONNEX […]readmore
Tags : Cognitive Impairment
Shots: The P-II study involves assessing of BI 425809 (4 oral doses, qd) vs PBO over 12wks. treatment period in schizophrenia patients. The results are presented at the 33rd ECNP […]readmore